Evaluation of the Intravenous Tissue Plasminogen Activator Treatment Algorithm of Nursing Intern Students

July 15, 2022 updated by: OZGE SOYDANER, Dokuz Eylul University

Evaluation of the Intravenous Tissue Plasminogen Activator Treatment Algorithm of Nursing Intern Students and Evaluation of the Efficiency of Simulation Method in the Development of Self-Efficacy Proficiency Levels

Intravenous (IV) tissue plasminogen activator (tPA) is one of the key elements of acute ischemic stroke. In this study, acute stroke patients maximum benefit from the treatment, intravenous tissue plasminogen activator (IV tPA) minimizing the errors related to the treatment of acute ischemic stroke patients of nursing students from clinical practice guides published on the treatment of It is aimed to be informed and to standardize nursing interventions.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Time management in acute stroke patients is possible with a multidisciplinary approach and team members who have received specific training for acute stroke patients. Studies have shown that the maximum result of treatment for acute stroke patients depends on nurses' ability to identify disease symptoms, plan and apply symptom-specific nursing care. There is evidence that the multidisciplinary presence of stroke teams in stroke units and the delivery of coordinated care during the acute phase improve patient outcomes . Coordinated care by the stroke team improves patient outcomes, reduces hospital costs, reduces patient readmission, and improves patient care quality.

Study Type

Interventional

Enrollment (Actual)

75

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • İzmir, Turkey
        • Ozge Soydaner

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Intern nursing student at Dokuz Eylül University

Exclusion Criteria:

Those who did not agree to participate in the study Those who were not be intern

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: intervention
Nursing intern students (n:39) will be given theory training about tPA treatment
Behavioral: theory training
theory training
Other Names:
  • tPA treatment knowledge of nursing students will increase
EXPERIMENTAL: Control
Nursing intern students (n:39) will be given theory training and simulation training about tPA treatment
Behavioral: theory training
theory training
Other Names:
  • tPA treatment knowledge of nursing students will increase
Behavioral: theory and simulation training
theory and simulation training
Other Names:
  • tPA treatment knowledge of nursing students will increase

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
self-efficacy scale
Time Frame: Change from baseline in Intravenous Tissue Plasminogen Activator Treatment knowledge and 2 weeks after intervention
Effectiveness change of Intravenous tissue plasminogen activator treatment knowledge after theoric teaching
Change from baseline in Intravenous Tissue Plasminogen Activator Treatment knowledge and 2 weeks after intervention
simulation scale
Time Frame: 2 weeks after simulation training
evaluation the simulation design
2 weeks after simulation training
tPA treatment information form
Time Frame: Change from baseline in Intravenous Tissue Plasminogen Activator Treatment knowledge and 2 weeks after intervention
Effectiveness change of Intravenous tissue plasminogen activator treatment knowledge after simulation and theoric teaching
Change from baseline in Intravenous Tissue Plasminogen Activator Treatment knowledge and 2 weeks after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dokuz Eylul University

Investigators

  • Study Director: GULSAH GUROL ARSLAN, Dokuz EU

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 1, 2020

Primary Completion (ACTUAL)

March 1, 2022

Study Completion (ACTUAL)

March 1, 2022

Study Registration Dates

First Submitted

March 23, 2022

First Submitted That Met QC Criteria

July 15, 2022

First Posted (ACTUAL)

July 18, 2022

Study Record Updates

Last Update Posted (ACTUAL)

July 18, 2022

Last Update Submitted That Met QC Criteria

July 15, 2022

Last Verified

December 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • tPA Treatment

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Stroke

Clinical Trials on theory training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe